4102-84-5

Basic information

• Product Name: 6-chloro-4-nitro-o-cresol
• Synonyms: 6-chloro-4-nitro-o-cresol;3-Chloro-2-hydroxy-5-nitrotoluene, 6-Chloro-4-nitro-o-cresol
• CAS NO: 4102-84-5
• Molecular Formula: C₇H₆ClNO₃
• Molecular Weight: 187.58044
• EINECS: 223-872-6
• Product Categories: Phenyls & Phenyl-Het
• Mol File: 4102-84-5.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 301.8°Cat760mmHg
• Flash Point: 136.3°C
• Appearance: /
• Density: 1.466g/cm³
• Vapor Pressure: 0.000369mmHg at 25°C
• Refractive Index: 1.61
• CAS DataBase Reference: 6-chloro-4-nitro-o-cresol(CAS DataBase Reference)
• NIST Chemistry Reference: 6-chloro-4-nitro-o-cresol(4102-84-5)
• EPA Substance Registry System: 6-chloro-4-nitro-o-cresol(4102-84-5)

Safety Data

• Hazardous Substances Data: 4102-84-5(Hazardous Substances Data)

Usage

General Description

6-chloro-4-nitro-o-cresol, also known as PCMC, is a chemical compound that is commonly used as a preservative in personal care and pharmaceutical products. It is a pale yellow solid with a slightly phenolic odor. PCMC is an effective antimicrobial agent, particularly against bacteria and fungi, and is commonly used in products such as soaps, shampoos, lotions, and skincare products. However,

InChI:InChI=1/C7H6ClNO3/c1-4-2-5(9(11)12)3-6(8)7(4)10/h2-3,10H,1H3

Upstream product

• 6265-03-8 2-amino-6-methyl-4-nitro-phenol 
• 99-53-6 2-methyl-4-nitrophenol 
• 95-48-7 ortho-cresol 
• 1123-64-4 2-chloro-6-methyl-[1,4]benzoquinone 
• 859495-20-8 5-chloro-6-hydroxy-toluene-3-sulfonic acid 
• 861366-88-3 2-chloro-6-methyl-[1,4]benzoquinone-4-oxime 

Downstream Products

• 55411-44-4 3-chloro-4-hydroxy-5-methyl aniline 

Relevant articles and documents

Identification of Diarylurea Inhibitors of the Cardiac-Specific Kinase TNNI3K by Designing Selectivity against VEGFR2, p38α, and B-Raf

A series of diarylurea inhibitors of the cardiac-specific kinase TNNI3K were developed to elucidate the biological function of TNNI3K and evaluate TNNI3K as a therapeutic target for the treatment of cardiovascular diseases. Utilizing a structure-based design, enhancements in kinase selectivity were engineered into the series, capitalizing on the established X-ray crystal structures of TNNI3K, VEGFR2, p38α, and B-Raf. Our efforts culminated in the discovery of an in vivo tool compound 47 (GSK329), which exhibited desirable TNNI3K potency and rat pharmacokinetic properties as well as promising kinase selectivity against VEGFR2 (40-fold), p38α (80-fold), and B-Raf (>200-fold). Compound 47 demonstrated positive cardioprotective outcomes in a mouse model of ischemia/reperfusion cardiac injury, indicating that optimized exemplars from this series, such as 47, are favorable leads for discovering novel medicines for cardiac diseases.

COMPOUNDS AND METHODS

Disclosed are compounds having the formula: wherein R1 and R2 are as defined herein, and methods of making and using the same.